Cardiology update 2016
In the latter half of 2016, the important trials were ATMOSPHERE, INOVATE-HF, and IMPEDANCE-HF. The inclusion of angiotensin receptor–neprilysin inhibitor (valsartan/sacubitril) and sinoatrial node modulator (ivabradine) in the guidelines was a significant change. HOPE-3 was a major trial in 2016 ex...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Journal of the Practice of Cardiovascular Sciences |
| Subjects: | |
| Online Access: | http://www.j-pcs.org/article.asp?issn=2395-5414;year=2016;volume=2;issue=2;spage=75;epage=78;aulast=Verma |